The role of serum HER2 as an alternative to fluorescence in situ hybridization for HER2 in metastatic breast cancer.

被引：0
|
作者：
Kong, SY [1 ]
Kwon, Y [1 ]
Lee, DH [1 ]
Lee, JS [1 ]
Lee, ES [1 ]
Ro, J [1 ]
机构：
[1] Natl Canc Ctr, Goyang, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：48S / 48S
页数：1
相关论文
共 50 条
  • [1] Correlation of In Situ HER2 RNA Expression With HER2 Immunohistochemistry and Fluorescence In Situ Hybridization Categories in Breast Cancer
    Tseng, Yu-Fen
    Li, Yu-Chia
    Lee, Yi-Hsuan
    Hu, Hsiang-We
    Zhang, Man-San
    Hung, Tze-Chun
    Lien, Huang-Chun
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2024, 148 (03) : e48 - e56
  • [2] HER2 overexpressing metastatic breast cancer.
    Spigel D.R.
    Burstein H.J.
    Current Treatment Options in Oncology, 2002, 3 (2) : 163 - 174
  • [3] Prognostic role of plasma HER2 gene copy number in patients with HER2 positive metastatic breast cancer.
    Ran, Ran
    Huang, Wenfa
    Lin, Shao
    Niu, Yunyun
    Rugo, Hope S.
    Kong, Weiyao
    Bo, Shiping
    Lu, Sijia
    Li, Huiping
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] Tolerability of neratinib in older adults with HER2 positive or HER2 mutated metastatic breast cancer.
    Lee, Jin Sun
    Yost, Susan Elaine
    Stiller, Tracey
    Blanchard, Suzette
    Padam, Simran
    Katheria, Vani
    Tang, Aileen
    Martinez, Norma
    Patel, Niki Himat
    Sedrak, Mina S.
    Waisman, James Ross
    Li, Daneng
    Sanani, Shamel
    Presant, Cary A.
    Mortimer, Joanne E.
    Yuan, Yuan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [5] Serial measurement of serum extracellular domain of HER2 (ECD/HER2) has prognostic value in metastatic breast cancer.
    Bramwell, V. H. C.
    Doig, G. S.
    Tuck, A. B.
    Wilson, S. M.
    Tonkin, K. S.
    Tomiak, A.
    Perera, F.
    Vandenberg, T. A.
    Chambers, A. F.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S40 - S40
  • [6] Predictive Value of HER2 Fluorescence In Situ Hybridization (FISH) Result in HER2 Positive Breast Cancer Response to Neoadjuvant Therapy
    Zhao, Jing
    Suo, Aili
    Zhang, Chao
    Shi, Quiying
    Wei, Zhimin
    Li, Zaibo
    Li, Xiaoxian
    MODERN PATHOLOGY, 2019, 32
  • [7] Predictive Value of HER2 Fluorescence In Situ Hybridization (FISH) Result in HER2 Positive Breast Cancer Response to Neoadjuvant Therapy
    Zhao, Jing
    Suo, Aili
    Zhang, Chao
    Shi, Qiuying
    Wei, Zhimin
    Li, Zaibo
    Li, Xiaoxian
    LABORATORY INVESTIGATION, 2019, 99
  • [8] Comparison of fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) for the evaluation of HER2/neu in breast cancer.
    Jacobs, TW
    Barnes, MJ
    Yaziji, H
    Gown, AM
    Schnitt, SJ
    LABORATORY INVESTIGATION, 1999, 79 (01) : 23A - 23A
  • [9] Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate
    Fornier, MN
    Seidman, AD
    Schwartz, MK
    Ghani, F
    Thiel, R
    Norton, L
    Hudis, C
    ANNALS OF ONCOLOGY, 2005, 16 (02) : 234 - 239
  • [10] Silver-Enhanced In Situ Hybridization as an Alternative to Fluorescence In Situ Hybridization for Assaying HER2 Amplification in Clinical Breast Cancer
    Park, Kyeongmee
    Han, Sehwan
    Kim, Jung-Yeon
    Kim, Hyun-Jung
    Kwon, Ji Eun
    Gwak, Geumhee
    JOURNAL OF BREAST CANCER, 2011, 14 (04) : 276 - 282
12345